Lv2
120 积分 2025-10-14 加入
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
12小时前
待确认
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
20天前
已完结
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
1个月前
已关闭
Two decades of pegfilgrastim: what have we learned? Where do we go from here?
1个月前
已完结
Evolving Trends in Surgically Managed Lung Cancer: A 16-Year Hospital-Based Epidemiological Analysis
2个月前
已完结
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC
4个月前
已完结
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort
4个月前
已完结
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
4个月前
已完结
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
5个月前
已完结
Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia
5个月前
已完结
皖公网安备34019202002308
